UY30056A1 - Administracion transdermica de meptazinol - Google Patents

Administracion transdermica de meptazinol

Info

Publication number
UY30056A1
UY30056A1 UY30056A UY30056A UY30056A1 UY 30056 A1 UY30056 A1 UY 30056A1 UY 30056 A UY30056 A UY 30056A UY 30056 A UY30056 A UY 30056A UY 30056 A1 UY30056 A1 UY 30056A1
Authority
UY
Uruguay
Prior art keywords
meptazinol
transdermal administration
increases
analgesic relief
amount effective
Prior art date
Application number
UY30056A
Other languages
English (en)
Spanish (es)
Inventor
Richard J Franklin
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of UY30056A1 publication Critical patent/UY30056A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
UY30056A 2005-12-21 2006-12-21 Administracion transdermica de meptazinol UY30056A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75335705P 2005-12-21 2005-12-21
US86211406P 2006-10-19 2006-10-19

Publications (1)

Publication Number Publication Date
UY30056A1 true UY30056A1 (es) 2007-06-29

Family

ID=38198475

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30056A UY30056A1 (es) 2005-12-21 2006-12-21 Administracion transdermica de meptazinol

Country Status (15)

Country Link
US (1) US20070224253A1 (fr)
EP (1) EP1962817B1 (fr)
AR (1) AR058598A1 (fr)
AT (1) ATE488229T1 (fr)
AU (1) AU2006331596A1 (fr)
CA (1) CA2633369A1 (fr)
DE (1) DE602006018355D1 (fr)
DK (1) DK1962817T3 (fr)
EA (1) EA200801575A1 (fr)
MX (1) MX2008008050A (fr)
PE (1) PE20071163A1 (fr)
PT (1) PT1962817E (fr)
TW (1) TW200800223A (fr)
UY (1) UY30056A1 (fr)
WO (1) WO2007075883A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
WO2009073734A2 (fr) 2007-12-03 2009-06-11 Medipacs, Inc. Dispositif de mesure de fluide
US20090186832A1 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
US9913806B2 (en) * 2008-06-25 2018-03-13 Fe3 Medical, Inc. Patches and methods for the transdermal delivery of a therapeutically effective amount of iron
US8961492B2 (en) 2009-02-12 2015-02-24 Incube Labs, Llc System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation
US8348922B2 (en) * 2009-02-12 2013-01-08 Incube Labs, Llc Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent
US8190252B2 (en) 2009-02-12 2012-05-29 Incube Labs, Llc Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
US8417330B2 (en) * 2009-06-26 2013-04-09 Incube Labs, Llc Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use
US8903485B2 (en) 2009-08-06 2014-12-02 Incube Labs, Llc Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes
WO2011032011A1 (fr) 2009-09-10 2011-03-17 Medipacs, Inc. Actionneur à faible encombrement et méthode améliorée d'administration d'agents thérapeutiques commandée par le soignant
US8685038B2 (en) 2009-12-07 2014-04-01 Incube Labs, Llc Iontophoretic apparatus and method for marking of the skin
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
WO2011094814A1 (fr) 2010-02-05 2011-08-11 Phosphagenics Limited Vecteur comprenant du phosphate de tocophéryle non neutralisé
WO2011100376A2 (fr) 2010-02-10 2011-08-18 Incube Labs, Llc Procédés et architecture pour l'optimisation de puissance d'une administration transdermique iontophorétique de médicament
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
EP2685992A4 (fr) 2011-03-15 2014-09-10 Phosphagenics Ltd Amino-quinoléines en tant qu'inhibiteurs de kinase
EP3626304A1 (fr) 2011-03-24 2020-03-25 Incube Labs, Llc Système et procédé d'administration transdermique iontophorétique biphasique d'agents thérapeutiques
WO2012154704A2 (fr) 2011-05-06 2012-11-15 Incube Labs, Llc Système et procédé d'administration transdermique iontophorétique biphasique d'agents thérapeutiques, dans la régulation des états de manque dus à l'accoutumance
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
CN104302689A (zh) 2012-03-14 2015-01-21 麦德医像公司 含有过量活性分子的智能聚合物材料
EP2961469A4 (fr) 2013-02-28 2016-10-26 Kimberly Clark Co Dispositif d'administration de médicament
CN105073179B (zh) 2013-02-28 2019-03-19 索伦托治疗有限公司 经皮药物递送装置
US10376308B2 (en) 2015-02-05 2019-08-13 Axon Therapies, Inc. Devices and methods for treatment of heart failure by splanchnic nerve ablation
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
EP3490442A4 (fr) 2016-07-29 2020-03-25 Axon Therapies, Inc. Dispositifs, systèmes et procédés pour le traitement de l'insuffisance cardiaque par ablation du nerf splanchnique
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
WO2019118976A1 (fr) 2017-12-17 2019-06-20 Axon Therapies, Inc. Méthodes et dispositifs d'ablation endovasculaire d'un nerf splanchnique
CA3089217A1 (fr) 2018-01-26 2019-08-01 Dorin Panescu Methodes et dispositifs pour l'ablation endovasculaire d'un nerf splanchnique
CA3134204A1 (fr) 2019-06-20 2020-12-24 Anisha BAPNA Methodes et dispositifs pour l'ablation endovasculaire d'un nerf splanchnique
AU2021208701A1 (en) 2020-01-17 2022-07-07 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
CN113491675B (zh) * 2021-07-01 2023-05-23 北京航空航天大学 一种预防瘢痕的微针创口贴及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539277A (en) * 1977-09-16 1979-01-31 Wyeth John & Brother Ltd Hexahydro-1h-azepines
IE55189B1 (en) * 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
CA2336682C (fr) * 1998-07-07 2006-10-10 Transdermal Technologies, Inc. Compositions d'administration transdermique rapide et non irritante d'agents pharmaceutiques actifs et methodes pour la formulation de ces compositions et leur administration
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE10059415A1 (de) * 2000-11-30 2002-06-06 Gruenenthal Gmbh Verwendung von schwachen Opioiden und gemischten Opioidagonisten/-antagonisten zur Therapie der Harninkontinenz
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형

Also Published As

Publication number Publication date
EP1962817B1 (fr) 2010-11-17
TW200800223A (en) 2008-01-01
CA2633369A1 (fr) 2007-07-05
WO2007075883A3 (fr) 2008-01-17
US20070224253A1 (en) 2007-09-27
ATE488229T1 (de) 2010-12-15
PE20071163A1 (es) 2007-11-30
WO2007075883A2 (fr) 2007-07-05
MX2008008050A (es) 2009-04-06
PT1962817E (pt) 2010-12-13
DK1962817T3 (da) 2011-03-07
AU2006331596A1 (en) 2007-07-05
EP1962817A2 (fr) 2008-09-03
EA200801575A1 (ru) 2008-12-30
WO2007075883A9 (fr) 2007-08-23
AR058598A1 (es) 2008-02-13
DE602006018355D1 (de) 2010-12-30

Similar Documents

Publication Publication Date Title
UY30056A1 (es) Administracion transdermica de meptazinol
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
DOP2012000238A (es) Compuestos de para la inhibición de inmunoproteasomas
MA32934B1 (fr) Combinaisons inhibitrices hsp90
GT200900023BA (es) Formas de dosificación farmacéutica
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2011003347A1 (es) Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides.
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
BR112012028136A2 (pt) terapia de combinaçao
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
CO7071139A2 (es) Tratamiento contra el cáncer cerebral
CL2015002847A1 (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides (divisional de la solicitud n° 0110-2015).
GT201200247A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
CR11418A (es) Trans-clomifeno para el sindrome metabolico
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112013012117A8 (pt) Sistema de distribuição de fármaco iontoforético coempacotado de utilização única coempacotado autocontido, usos de fármaco e de composto de triptano
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
GT201400003A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
MX2020003665A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.
UY31335A1 (es) Tratamiento de sintomas vasomotores
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
MA32933B1 (fr) Combinaison d'inhibiteurs de hspo90 et d'herceptine
AR066076A1 (es) Procedimiento para dosificar sistemas de liberacion de farmacos auto-emulsionantes
GT200800208A (es) Composición farmacèutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160930